Zolmitriptan Tablet, Film Coated
Product Images NDC 68001-250

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zolmitriptan (NDC 68001-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Zolmitriptan Tablets, 2.5 mg 6 Unit Dose Ndc 68001-249-01 (Carton Zolmitriptan Tablets 2 5 mg Rev 0714)

Zolmitriptan Tablets, 2.5 mg 6 Unit Dose Ndc 68001-249-01 (Carton Zolmitriptan Tablets 2 5 mg Rev 0714)
Packaging label for Zolmitriptan Tablets, USP 2.5 mg by BluePoint Laboratories. The label indicates the product is a prescription oral film-coated tablet, with 6 unit-dose tablets per package. Manufacturer details include Glenmark Pharmaceuticals Ltd., India. Warnings and storage instructions are also noted on the label.*
FDA Label Image

Zolmitriptan Tablets 5mg Ndc 68001-250-01, 3 Unit Dose Tablets (Carton Zolmitriptan Tablets 5 mg Rev 0714)

Zolmitriptan Tablets 5mg Ndc 68001-250-01, 3 Unit Dose Tablets (Carton Zolmitriptan Tablets 5 mg Rev 0714)
Packaging label for Zolmitriptan Tablets, USP 5 mg oral film-coated tablets. The label shows the BluePoint Laboratories logo and indicates the package contains 3 unit-dose tablets. It provides storage instructions, manufacturer information (Glenmark Pharmaceuticals Ltd., India), and barcode details. The label highlights that each tablet contains 5 mg of zolmitriptan and is for prescription use only.*
FDA Label Image

Zolmitriptan Structual Formula (E6628b7a 0b63 4e6f A5e7 2fa195265235 01)

Zolmitriptan Structual Formula (E6628b7a 0b63 4e6f A5e7 2fa195265235 01)
Chemical structure of zolmitriptan, a human prescription drug active ingredient, shown as a molecular diagram with indicated rings and functional groups.*
FDA Label Image

Figure 1 (E6628b7a 0b63 4e6f A5e7 2fa195265235 02)

Figure 1 (E6628b7a 0b63 4e6f A5e7 2fa195265235 02)
A line graph depicting the estimated probability of response over time from initial dose for zolmitriptan and placebo. The x-axis represents time in hours (0 to 4), and the y-axis shows the estimated probability of response in percentage (0% to 100%). Four lines compare placebo, zolmitriptan 1 mg, 2.5 mg, and 5 mg, with response increasing more rapidly and to a higher extent for zolmitriptan doses than placebo.*
FDA Label Image

Figure 2 The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 2, 3, And 5 (E6628b7a 0b63 4e6f A5e7 2fa195265235 03)

Figure 2 The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 2, 3, And 5 (E6628b7a 0b63 4e6f A5e7 2fa195265235 03)
A line graph shows the estimated probability of medication rescue over 24 hours after the initial dose of Zolmitriptan at 1 mg, 2.5 mg, and 5 mg, compared with placebo. The x-axis represents time in hours, and the y-axis is the estimated probability percentage, with higher doses generally showing different curves.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.